After FNAC confirms malignancy (C5), a core needle biopsy is the most appropriate next step to determine ER, PR, HER2 receptor status and histological type. This is essential for planning neoadjuvant vs adjuvant therapy.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.